drugset
drugset / Trial / NCT05644093

IM and IV SPL026 Drug Product in Healthy Participants

NCT05644093 ↗

Phase 1 Completed 14 enrolled Small Pharma Ltd
Non-randomizedCrossoverOpen-labelTreatment

Summary

The goal of this clinical trial is to test SPL026 given via injection into a muscle in healthy volunteers.

Timeline

Start
2023-01-03
Primary completion
2023-04-05
Completion
2023-04-05

Drugs

EvaluationDrugModalityDoseRoute
Subject SPL026 Unknown — Intravenous

Indications

major depressive disorder